|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Pilot Clinical Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
This clinical trial aims to characterize the safety of OL-101 and establish the recommended dose for future research and to evaluate the efficacy of OL-101 (Dose expansion).
100 Clinical Results associated with Allogene Overland Therapeutics (PRC) Co., Ltd.
0 Patents (Medical) associated with Allogene Overland Therapeutics (PRC) Co., Ltd.
100 Deals associated with Allogene Overland Therapeutics (PRC) Co., Ltd.
100 Translational Medicine associated with Allogene Overland Therapeutics (PRC) Co., Ltd.